In AML-MRC-C, the presence of TP53 mutations and MR mutations was negatively correlated: ASXL1, BCOR, EZH2, SRSF2, and U2AF1 showed significantly lower mutation rates when TP53 was mutated compared to cases with wildtype TP53 (chi-square test; ASXL1: p < 0.001, BCOR: p = 0.006, EZH2: p = 0.030, SRSF2: p < 0.001, U2AF1: p = 0.014, Supplementary Fig. 2). The gene discussed is NR3C2; the disease is acute myeloid leukemia.